Melanoma: Keeping up with increasing incidence

The incidence of melanoma is increasing faster than any other cancer.1 Although most cases are treated early, 5-year survival rates for patients with metastatic disease remain low.2

Indoximod research targets advanced melanoma3

NewLink Genetics’ indoximod is a small-molecule indoleamine 2,3-dioxygenase (IDO) pathway inhibitor that has the potential to disrupt mechanisms by which tumors evade the immune system.4,5

 
Learn about the IDO pathway and IDO pathway inhibitors

 
metastatic-melanoma-n96

Learn more about the indoximod study in advanced melanoma

 

References

1. Medscape. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. www.medscape.com/viewarticle/470300. Accessed October 3, 2015. 2. American Cancer Society. Melanoma skin cancer. http://www.cancer.org/acs/groups/cid/documents/webcontent/003120-pdf.pdf. Revised March 20, 2015. Accessed October 4, 2015. 3. National Institutes of Health. Study of IDO inhibitor in combination with ipilimumab for adult patients with metastatic melanoma. http://clinicaltrials.gov/ct2/show/record/NCT02073123. Accessed October 4, 2015. 4. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34(3):137-143. 5. Baban B, Chandler PR, Sharma MD, et al. IDO activates regulatory T cells and blocks their conversion into Th17-like helper T cells. J Immunol. 2009;183(4):2475-2483.